Marco Rochat's Contact Details

Marco Rochat's Company Details

Axalbion Therapeutics Limited

Manchester, England, United Kingdom • 4 Employees
Pharmaceuticals

Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with unmet needs and multi-billion-dollar markets.Its molecules have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes.Axalbion's s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population. It has already been tested in a Phase 2a trial with patients suffering from refractory chronic cough.Axalbion benefits from having proof of concept studies (clinical and non-clinical), strong safety and toxicology data, and the support of world's leading experts and strategic partners.WE WELCOME PRIVATE INVESTORS AND VC's TO CONTACT US DIRECTLY FOR FURTHER DETAILS.contact@axalbion.com